Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab with bortezomib, cyclophosphamide and dexamethasone in multiple myeloma with extramedullary disease
2019-000991-41Phase 2Active
- Sponsor
- Stichting European Myeloma Network
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Stichting European Myeloma Network. Primary endpoint: Complete response rate. Started Jul 2019; status: active.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-000991-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000991-41.